Financial Implications Of Mergers

AstraZeneca just made a $555M AI pact with a San Francisco biotech - no clinical programs. No approved drugs. Just ONE thing that made every boardroom take notice: AstraZeneca has been steadily expanding its AI footprint. In 2025 alone, it announced a $5.3B AI deal with CSPC and a $200M oncology partnership with Tempus and Pathos AI. And now they just made one of their boldest platform bets yet. AstraZeneca just signed a $555M partnership with Algen Biotechnologies, a San Francisco biotech with zero approved products. What did they see? A platform so powerful it could generate dozens of drug targets continuously. Algen's platform is called AlgenBrain. It combines AI with CRISPR-based functional genomics to map how genes regulate immune pathways. These aren't one-off discoveries. AlgenBrain is a discovery engine that can continuously generate new targets for immune-mediated diseases. That means multiple shots on goal, not just a single product. For a partnership with no clinical data, that's rare. But this wasn't a product bet. It was a platform bet. Under the deal, Algen identifies and validates new immunology targets while AstraZeneca gains exclusive rights to develop therapies against them. Total value up to $555M in upfront and milestone payments. What's most striking is the stage where this partnership begins: before any drug programs exist. Target identification is one of the least predictable phases of R&D. Platforms like Algen's can shorten that timeline, lower attrition, and strengthen first-in-class potential across multiple indications. Milestone-based payments align both sides on long-term success while limiting AstraZeneca's risk. Pharma companies are moving upstream. They're partnering with AI platforms to build continuous discovery capacity rather than buying late-stage assets. The next wave of biopharma M&A won't chase blockbusters, it'll chase the systems that create them. After working on 90+ deals over 25 years, I'm watching this trend accelerate faster than most realize. 3 takeaways if you're building in biotech: • Platform over product. Scalable discovery commands premium value. • Structure for milestones. Balance reward and risk through staged terms. • Secure early alliances. First access often defines long-term differentiation. And if you're investing, this deal redefines value. It's not just about late-stage efficacy data, it's about solving upstream bottlenecks.

AbbVie Reportedly Nears $11 Billion Acquisition of Apogee Therapeutics According to reporting from the Financial Times, AbbVie is closing in on an acquisition of Apogee Therapeutics valued at approximately $10.9 billion in cash, representing a premium of roughly 60% over Apogee's closing share price. If completed, it would be one of AbbVie's largest acquisitions in recent years and another major healthcare deal in what has already been an active year for pharmaceutical M&A. I'll leave the science to people like my friend Gregory Austin. What caught my attention is the economics behind the transaction. Developing a new medicine can take more than a decade, cost billions of dollars, and still fail in clinical trials. Acquiring a company with promising late-stage assets allows an established pharmaceutical company to purchase years of research, scientific expertise, and future revenue potential rather than starting from scratch. Patents give pharmaceutical companies a limited period of exclusivity before lower-cost competitors enter the market. As blockbuster drugs approach the end of that window, companies need new therapies capable of replacing future revenue. Acquiring innovative biotechnology firms is often one of the fastest ways to strengthen that pipeline. This transaction could have implications beyond AbbVie. A premium acquisition signals how highly large pharmaceutical companies value innovation. If attractive biotechnology companies become increasingly scarce, competitors may respond by pursuing acquisitions of their own rather than relying solely on internal research and development, supporting continued consolidation across the industry. The deal also highlights a broader shift in how the industry operates. Smaller biotech firms increasingly focus on scientific discovery, while larger pharmaceutical companies provide the capital, regulatory expertise, manufacturing, and global commercial infrastructure needed to bring successful therapies to market. Whether this transaction ultimately proves successful will depend on the clinical performance of Apogee's therapies and AbbVie's execution. But from an economic perspective, it reflects a broader trend: companies are increasingly choosing to acquire innovation rather than build every piece of it themselves. At Havas Edge, we follow transactions like this because they provide insight into how executives allocate capital. The prices companies are willing to pay for innovation often reveal where they believe future growth and competitive advantage will come from.

3 major MASH acquisitions in under a year. Roche, GSK, now Novo. Combined value over $9B. The market's sending a clear signal: MASH has moved from speculative to strategic necessity. Here's the competitive dynamic playing out: Novo owns GLP-1s. Wegovy and Ozempic generate tens of billions annually. MASH frequently stems from obesity. Acquiring Akero Therapeutics efruxifermin gives them both ends of the treatment spectrum. They can address the obesity AND the downstream liver damage. No one else has that combination. Roche paid $3.5B for 89Bio's pegozafermin last month. Similar mechanism to efruxifermin (FGF21 analog). They're betting on a parallel path to the same market. The clinical data showed comparable efficacy, so Roche bought its way into the race rather than starting 5 years behind. GSK grabbed Boston Pharmaceuticals experimental MASH drug for $1.2B upfront earlier this year. Different mechanism (THR-β agonist), potentially complementary to FGF21 approaches. They're hedging on mechanism diversity. What this tells us: The big pharma companies with deep metabolic disease franchises have decided MASH can't be ignored anymore. The patient population is massive (6-8% globally), growing with obesity rates, and there's almost no effective treatment currently available. The companies that waited are now paying premiums to catch up. Novo Nordisk's 16% premium looks reasonable until you factor in the 42% run-up from acquisition speculation. Roche paid a 127% premium for 89bio. GSK went straight to a $1.2B upfront payment before the asset even hit meaningful clinical milestones. Early movers got better deals. Late movers are paying for speed. The next 3-5 years will determine which mechanisms actually work in MASH. Multiple programs have failed spectacularly. The ones that succeed will define a $10B+ market. The ones that fail will write off billions in acquisition costs. But here's what's interesting: None of these companies could afford NOT to play. If MASH programs succeed and you're not in the game, you've ceded an entire treatment category to competitors. The cost of missing this market is higher than the cost of buying in. We're watching portfolio strategy play out in real time. Companies aren't just buying drugs. They're buying optionality on a market that might explode or might collapse, and they've decided the risk of missing it is worse than the cost of entry. What do you think drives the better ROI here - mechanism diversity or doubling down on proven approaches like FGF21? #Biotech #Pharma #Strategy #MASH #M&A

𝗠𝗼𝗿𝗲 𝗳𝗶𝗰𝘁𝗶𝗼𝗻 𝗵𝗮𝘀 𝗯𝗲𝗲𝗻 𝘄𝗿𝗶𝘁𝘁𝗲𝗻 𝗶𝗻 𝗘𝘅𝗰𝗲𝗹 𝘁𝗵𝗮𝗻 𝗶𝗻 𝗪𝗼𝗿𝗱. Excel tells great stories; the nightmare is discovering the seller filed it under non-fiction. Where the M&A story is most likely to unravel post close: • Financial-statement warranties • Tax liabilities • Working-capital true-ups • Earn-out calculations These four flashpoints drive most real-world SPA disputes. 𝗞𝗲𝘆 𝗺𝗶𝘁𝗶𝗴𝗮𝘁𝗶𝗼𝗻 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗲𝘀: ➡️ 𝗙𝗗𝗗 - Make it forensic not polite; focus on your FDD like your life depends on it. Chase every headline figure to a source doc; variance = price chip or escrow. ➡️𝗠𝗼𝗱𝗲𝗹 𝘄𝗼𝗿𝘀𝘁-𝗰𝗮𝘀𝗲, 𝗻𝗼𝘁 𝘄𝗶𝘀𝗵-𝗰𝗮𝘀𝗲 - Run a downside DCF and check covenants still hold; deal fever is cheaper to treat pre-signing. ➡️𝗟𝗶𝘁𝗶𝗴𝗮𝘁𝗼𝗿𝘀 𝗮𝗿𝗲 𝘆𝗼𝘂𝗿 𝗳𝗿𝗶𝗲𝗻𝗱 - Have litigators review the SPA as they spot dispute triggers that transaction lawyers miss. Don't be the meme. ➡️𝗗𝗼𝗰𝘂𝗺𝗲𝗻𝘁 𝘁𝗵𝗲 𝘃𝗮𝗹𝘂𝗮𝘁𝗶𝗼𝗻 𝗺𝗮𝘁𝗵𝘀 - One memo: equity bridge, EBITDA tweaks, all assumptions - future you will thank present you. ➡️𝗡𝗮𝗶𝗹 𝘁𝗵𝗲 𝗽𝗿𝗶𝗰𝗲 𝗺𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺 𝗲𝗮𝗿𝗹𝘆 - Locked-box for steady cashflows; completion accounts for volatility. ➡️𝗣𝗠𝗜 - Start post-merger integration planning on day 1 of your DD. PMI teams look under the bonnet in a different way and can spot issues your external advisors may miss. Good PMI will also help surface any disputes early - before you've released any holdback or a claims period has expired. ➡️𝗗𝗲𝗳𝗶𝗻𝗲 𝗳𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗺𝗲𝘁𝗿𝗶𝗰𝘀 𝘄𝗶𝘁𝗵 𝘀𝘂𝗿𝗴𝗶𝗰𝗮𝗹 𝗽𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 - This is often negotiated up until the wire when deal fatigue has kicked in. Get this sorted early, with worked examples in the SPA ➡️𝗪&𝗜 - Consider insurance early on in the process so there are no surprises re coverage gaps or exclusions for poor DD. Cover has never been so cheap or broad - a lot has changed in the last few years. ➡️𝗦𝘁𝗿𝗲𝘀𝘀-𝘁𝗲𝘀𝘁 𝘁𝗵𝗲 𝘁𝗮𝘅 𝗽𝗼𝘀𝗶𝘁𝗶𝗼𝗻 - R&D credits, unpaid liabilities, cross-border VAT. ➡️𝗕𝘂𝗶𝗹𝗱 𝗿𝗲𝗮𝗹 𝗯𝘂𝗳𝗳𝗲𝗿𝘀 - Escrow, holdback, indemnities, W&I. ➡️𝗗𝗶𝘀𝗽𝘂𝘁𝗲𝘀 - Have a clear fast track disputes process for price adjustments and earn-outs. Name an accounting expert, cap fees, and mandate a 90-day timetable - litigation lite beats litigation long. ➡️ 𝗥𝗲𝗱-𝘁𝗲𝗮𝗺 𝘆𝗼𝘂𝗿 𝗽𝗿𝗼𝗰𝗲𝘀𝘀 – Appoint someone to stress-test strategy and drafting. Constructive friction protects the client more than harmony ➡️ 𝗢𝘄𝗻 𝘁𝗵𝗲 𝗻𝗮𝗿𝗿𝗮𝘁𝗶𝘃𝗲 – Even if you can't fix known issues, shape the story early. Silence reads as deception; context turns problems into priced risks ❓ What would you add? * Full disclosure - I saw this meme on Litigation God years ago - it still makes me laugh. Obviously, because it's not true!

Big pharma dropped $6.6B on in-vivo CAR-T startups in under a year. But this only a small niche compared to the entire Biotech M&A space. For In Vivo cell engineering From March until last October: Bristol Myers Squibb → Orbital Therapeutics ($1.5B) Gilead/Kite → Interius ($350M) + Pregene ($1.64B) AbbVie → Capstan Therapeutics ($2.1B) AstraZeneca → EsoBiotec ($1B) So why Big Pharma prefers to buy instead of build own R&D programs? Three reasons small biotechs win at innovation: #1 Cost advantage Big pharma's overhead is massive. Executive layers, complex infrastructure, global operations. A fully loaded FTE at J&J costs far more than at a 50-employee biotech. Small companies run lean and hungry. #2 Laser focus Big pharma kills programs at the first sign of trouble. "Fail early" sounds smart, but most successful drugs survived near-death moments. Small biotechs can't afford to quit. They only have 1-2 programs. That desperation breeds breakthroughs. #3 Organizational alignment Ever heard of the organizational iceberg? In large companies, only 4% of problems reach senior management. In a startup, the CEO knows everything happening at the bench. No layers. No information loss. Everyone's aligned on the mission. As a curious note you can read about the critical operational number defined by Dunbar (link below). In 2024, only 23 of 55 FDA approvals came from companies with $3B+ in sales. Small biotechs are outinnovating giants. Big pharma just figured this out. Why fund 10 risky programs internally when you can let the market fund 100 and cherry-pick the winners? It's not laziness. It's strategy. What's your take?

I've spent my professional life developing, advocating for, and writing about multi-institutional initiatives in higher education in both formally organized systems and voluntary collaboratives. Their benefits are measurable in terms of cost, impact, and reach, and they clearly enable institutions to perform functions they cannot afford to perform as well or as easily on their own. But in these troubled times, I had to know: do they help institutions address the risks arising from intensifying demographic, financial, and political pressures they are facing? Data underpinning my analyses of risk and resilience in US university and college systems offer a unique opportunity to swing at an answer. What do they show? The short answer is yes. Shared services help systems address financial risk and may even differentiate winning and losing systems in the years ahead. But there's a catch. They only work in this way if built before acute financial pressures arrive. Built under duress, they will reduce damage but won't materially address the structural conditions that prompted their construction. There are lessons here for system leaders, boards, and legislators, who are urged in this blog to evaluate their systems' shared service portfolios and strengthen them before a crisis arrives, forcing them onto the wrong side of a widening gap between the at-risk and the resilient. https://lnkd.in/ep6gE-QK

In Food & Beverage (F&B) mergers and acquisitions, prioritizing a profitable business (bottom line) over mere revenue growth (top line) is critical because high-revenue, low-margin businesses are often unsustainable and difficult to integrate. In a sector often facing tight margins, rising input costs, and high failure rates, acquiring profit ensures the acquisition adds value rather than just scale.  Key Reasons for Prioritizing Profit over Top Line in F&B M&A: Sustainability vs. "Leaky Bucket": In the F&B industry, adding high revenue without profit is likened to "putting water into a leaky bucket." A company may be growing top-line sales through excessive discounting or high marketing spend, which actually erodes profitability. Operational Efficiency (EBITDA Margin): Acquirers now focus more on EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) margins rather than just sales. A profitable business demonstrates efficient cost management, good supplier relationships, and high customer retention, making it a more secure investment. Operational Risk: A high-top-line business with low profit often hides operational inefficiencies, such as excessive waste, poor labor management, or high cost of goods sold (COGS). Merging with such a business can dilute the acquirer’s profitability. Valuation Accuracy: Mergers based solely on revenue often lead to overvaluation. Prioritizing profitability ensures that the acquisition price reflects the actual cash flow and financial health of the business. Market Trends Post-Pandemic: Post-pandemic, F&B mergers have shifted from "growth at all costs" to a more disciplined approach focusing on financial stability, resilience, and sustainable margins.  What to Focus on Instead of Top Line: Gross Profit Margin: Measures how efficiently a company turns sales into profit after accounting for COGS (raw materials, direct labor). Unit Economics: Ensures that individual stores or product lines are profitable on their own, not just profitable in aggregate due to subsidies. Customer Loyalty/Retention: Strong, organic customer loyalty indicates a sustainable brand, whereas high revenue driven by temporary discounts is volatile.  In summary, in F&B M&A, profitability proves the business model works, while top-line revenue only shows that the product is popular. 

Only 35-40% of nonprofits would ever consider a merger. The rest are waiting to see if things get better. Things are not getting better. I made a video last year — "What will nonprofits look like in 2035?" — and one of my predictions was this: 𝗼𝗿𝗴𝗮𝗻𝗶𝘇𝗮𝘁𝗶𝗼𝗻𝘀 𝘁𝗵𝗮𝘁 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗲 𝘄𝗶𝗹𝗹 𝘀𝘂𝗿𝘃𝗶𝘃𝗲. Many that don't collab are either sitting on millions in reserves and never needed to, or they're at risk of closing. We're already seeing it. Layoffs. Closures. And it's not slowing down. This week on The Small Nonprofit podcast, I talk with Jon Hoffmann about how to do mergers and collabs 𝘳𝘪𝘨𝘩𝘵. Most organizations wait until they're in crisis to have these conversations. But by then, the required relationships aren't built. The trust isn't there. And the leverage to actually build something better is long gone. The organizations that navigated this moment best started the conversations 𝘣𝘦𝘧𝘰𝘳𝘦 they needed to. Not a formal proposal. Not a merger announcement. Just an honest conversation with one adjacent ED: "𝘞𝘦'𝘳𝘦 𝘧𝘢𝘤𝘪𝘯𝘨 𝘵𝘩𝘦 𝘴𝘢𝘮𝘦 𝘱𝘳𝘦𝘴𝘴𝘶𝘳𝘦𝘴. 𝘞𝘩𝘢𝘵 𝘪𝘧 𝘸𝘦 𝘥𝘪𝘥𝘯'𝘵 𝘧𝘢𝘤𝘦 𝘵𝘩𝘦𝘮 𝘢𝘭𝘰𝘯𝘦?" That's the first move. Jon put it plainly: two bad balance sheets don't make a good one. A merger doesn't erase structural problems. But two mission-aligned organizations with genuine trust between them? That can produce something stronger than either alone. The nonprofit sector has trained us to treat organizational survival and mission survival as the same thing. They're not. So reflect on: 𝘄𝗵𝗮𝘁 𝗮𝗿𝗲 𝘄𝗲 𝗮𝗰𝘁𝘂𝗮𝗹𝗹𝘆 𝗽𝗿𝗼𝘁𝗲𝗰𝘁𝗶𝗻𝗴 — 𝘁𝗵𝗲 𝗺𝗶𝘀𝘀𝗶𝗼𝗻, 𝗼𝗿 𝘁𝗵𝗲 𝗶𝗻𝘀𝘁𝗶𝘁𝘂𝘁𝗶𝗼𝗻? Full conversation on the podcast. Link on my profile under Featured. Has this conversation come up at your org?

Are mergers the future of institutional sustainability......or a limited solution to a much larger set of challenges? This has been on my mind lately.... This morning on my way to campus, I was struck by a College Viability, LLC special edition podcast with Gary Stocker and guests Jonathan Nichols (author of Requiem for a College with a recent 2nd edition release), and publisher Kate Colbert. Nichols’ central warning landed hard: no institution is too loved or too good to fail. Closures, he emphasized, are rarely sudden (check out some fantastic writing by Unity Environmental President and innovation guru Dr. Melik Peter Khoury, who has said the same); they are decades in the making. Colbert added that the shame and secrecy surrounding struggling colleges often keep leaders from even acknowledging what’s happening and being remotely transparent, much less planning for it. Their conversation underscored that transparency, proactive governance, and student-centered decision-making are not optional.......they are survival tools. Which brings me to mergers. They are not a panacea, but they are an option worth serious consideration in today’s climate of declining demographics, rising costs, and fragile tuition models. Some recent examples stand out: - Mission-driven coalitions. Otterbein and Antioch formed the Coalition for the Common Good, keeping distinct undergraduate brands while collaborating on graduate programs and shared services. - System-level diversification. Lindenwood Education System brought Dorsey and Ancora into a nonprofit parent structure to expand workforce-aligned offerings. - Sector-wide adaptations. Catholic colleges and others have turned to mergers, acquisitions, and partnerships to confront demographic pressures and overcapacity. The benefits are real (at least on paper): broader programs, shared resources, expanded reach, and stronger competitiveness. But the challenges are equally daunting: cultural clashes, integration headaches, identity loss, and legal hurdles. As Ricardo Azziz and others note, success depends on clear vision, supportive boards, strong project management, agile and respected leadership, and above all, a student-first focus. The takeaway: Mergers should be on the table, not as desperation plays, but as part of strategic planning. Institutions that start these conversations early, with transparency and courage, may protect their missions and create new opportunities for students. Those who don’t risk becoming case studies in future editions of Requiem for a College.